SPER© THERAPEUTICS

NTM Drug Development: An Industry Perspective

Angela Talley, MD

FDA NTM Workshop

8 April 2019



Conflict of Interest Disclosure

• Angela Talley is a full time employee of Spero Therapeutics, Inc.




Opportunity

- Multiple candidate agents in existing and novel classes
 - -Gyrase inhibitors, macrolides, rifamycins, ethambutol, oxazolidinones, aminoglycosides, tetracyclines, BL-BLIs, others
- Increasing recognition of NTM as a chronic debilitating disease state
- Current SOC is inadequate, poorly tolerated
- Effective regimen(s) are urgently needed (can't wait 10 years)
- Unique opportunity to catalyze new development approach to get these agents to patients in need faster



Drug X: Clinical Development Path



Drug X: NTM Clinical Development

- Current status/understanding:
 - -The definitive efficacy endpoint(s) for NTM clinical trials are unclear
 - Sputum culture conversion as a surrogate endpoint may not be predictive of clinical benefit
 - Important to demonstrate a benefit to the patient via a clinically meaningful endpoint
 - Patient reported outcomes could be one method to evaluate clinical benefit, but the specific elements of the tool need to be defined
 - -Need for placebo in order to understand safety
- Development of clinical endpoints that reflect the early objectives of therapy may be more appropriate primary efficacy measures or part of a composite endpoint



Drug X Clinical Development: Key Questions

What are the objectives of treatment of pulmonary NTM?

Cure?	 Is durable microbiological response at 12, 18, 24 months an appropriate objective of therapy?
	W/bish summer and the second of
Symptomatic improvement on therapy?	 Which symptoms? How to measure? daily QoL: patient reported (PRO assessment tool) which one?, objective assessments functional status: FEVI/ 6MWT, other objective assessment?
Improvement or delay of disease progression?	 Is the duration of progression-free survival as compared with SOC a reasonable endpoint? If so, what is the appropriate measurement?
What is the appropriate timing for assessment of response?	 Should the primary endpoint reflect the early objectives of treatment on or at completion of therapy rather than durable response?



Drug X Clinical Development: Key Questions

Whom should we study?

- Salvage therapy in treatment-refractory patients or treatmentnaïve/inexperienced patients at the cusp of starting therapy?
- Pulmonary MAC or Pulmonary NTM? Subtypes?
- Are different populations appropriate for early (Phase 2) vs. pivotal trials?
- Which endpoints are appropriate to assess benefit?
 - What are the clinical outcome measures to assess "objective improvement of symptoms" (per consensus definition)?
 - —Which outcomes (clinical or microbiologic) are most appropriate as a primary efficacy endpoint?
 - -Are there population/patient-specific differences in endpoints?
 - -How do we evaluate a new NME vs. a new regimen?
- Timing/Feasibility: What is minimum treatment duration for a specific clinical or micro endpoint (or population) at which we might detect a meaningful difference?




Drug X: Efficacy vs. Comparators

- How do you standardize a background regimen in a treatment-refractory population particularly in an early efficacy assessment?
- Is it appropriate to add a single agent to a potentially failing SOC regimen?
- In what settings is a monotherapy vs. placebo trial design appropriate?
- Given the recruitment and feasibility challenges, are there the opportunities for platform trial collaboration to increase efficiency?
- What lessons can we learn from the MDR-TB experience? From regimen-building in HIV? Oncology?



More questions than answers...

The heterogeneity in the patterns of disease and the response to therapy may reflect our limited understanding of the pathophysiology of NTM-LD





NTM Drug Development: Addressing Barriers and Challenges

 Better understanding of pathophysiology of NTM lung disease and factors associated with disease progression/treatment response

- Collaboration to optimize the utility of existing data

- Better translation of preclinical data to clinically effective new combination regimens
 - Technology to identify promising compounds based on preclinical data (e.g. validation of hollow fiber)
 - Early identification of combination partners
- Feasible trial designs with earlier definitive primary endpoints
- Feasible development path for accelerated approval
- Development of validated Patient Reported Outcome measures
- Pathway for regimen-based development (MDR-TB parallels)

